Previous Article | Next Article 
Molecular and Cellular Biology, May 2001, p. 3436-3444, Vol. 21, No. 10
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.10.3436-3444.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Transcription Factor HIF-1 Is a Necessary Mediator
of the Pasteur Effect in Mammalian Cells
Tiffany N.
Seagroves,1
Heather
E.
Ryan,1
Han
Lu,1
Bradly G.
Wouters,2
Merrill
Knapp,3
Pierre
Thibault,4
Keith
Laderoute,3 and
Randall S.
Johnson1,*
Molecular Biology Section, Division of
Biology, University of California San Diego, La Jolla, California
920931; University of Ottawa and the
Ottawa Regional Cancer Centre, Ottawa, Ontario K1H
8L6,2 and Institute for Biological
Sciences, National Research Council of Canada, Ottawa, Ontario K1A
0R6,4 Canada; and SRI International,
Menlo Park, California 940253
Received 15 November 2000/Returned for modification 20 December
2000/Accepted 13 February 2001
 |
ABSTRACT |
The ability to respond to differential levels of oxygen is
important to all respiring cells. The response to oxygen deficiency, or
hypoxia, takes many forms and ranges from systemic adaptations to those
that are cell autonomous. Perhaps the most ancient of the
cell-autonomous adaptations to hypoxia is a metabolic one: the Pasteur
effect, which includes decreased oxidative phosphorylation and an
increase in anaerobic fermentation. Because anaerobic fermentation produces far less ATP than oxidative phosphorylation per molecule of
glucose, increased activity of the glycolytic pathway is necessary to
maintain free ATP levels in the hypoxic cell. Here, we present genetic
and biochemical evidence that, in mammalian cells, this metabolic
switch is regulated by the transcription factor HIF-1. As a result,
cells lacking HIF-1
exhibit decreased growth rates during hypoxia,
as well as decreased levels of lactic acid production and decreased
acidosis. We show that this decrease in glycolytic capacity results in
dramatically lowered free ATP levels in HIF-1
-deficient hypoxic
cells. Thus, HIF-1 activation is an essential control element of the
metabolic state during hypoxia; this requirement has important
implications for the regulation of cell growth during development,
angiogenesis, and vascular injury.
 |
INTRODUCTION |
Decreased environmental oxygen
forces cells and tissues to adapt in multiple ways. In response to
hypoxia, a significant number of changes in gene expression occur,
resulting in elevated transcription of angiogenic factors,
hematopoietic factors, and some metabolic enzymes (21).
The switch between the two forms of respiration utilized by animal
cells, aerobic versus anaerobic, was first noted by Pasteur in the late
19th century (12, 22). As the oxygen level decreases, the
generation of ATP shifts from the oxidative phosphorylation pathway in
the mitochondria to the oxygen-independent pathway of glycolysis in the
cytoplasm. Although glycolysis is less efficient than oxidative
phosphorylation in the generation of ATP, in the presence of sufficient
glucose glycolysis can sustain ATP production due to increases in the
activity of the glycolytic enzymes (12, 22). Perhaps
nowhere has this forced adaptation been the focus of so much study as
in transformed cells; this is because in solid tumors it is clear that
a large percentage of the cell population is at least transiently
hypoxic (1).
Earlier in the 20th century, Otto Warburg demonstrated that tumors
differed from normal tissues in their utilization of the glycolytic
pathway (26). For a given amount of glucose, tumor fragments ex vivo produced far more lactate than sections of
nontransformed tissues under normoxic conditions. In vivo the situation
is likely to be more complex. Within individual tumors, there are some
areas that may respond to hypoxia by exhibiting the normal
physiological switch to glycolysis similar to that employed by all
nontransformed cells in response to lowered oxygen levels.
Concurrently, many other areas of transformed cells in solid tumors may
adapt to hypoxia by permanently relying on glycolysis to survive,
regardless of subsequent exposure to normoxic oxygen levels. This
latter phenomenon is referred to as the Warburg effect. A mechanistic explanation for this phenomenon has come from studies that indicate that a tumor's increased dependence on glycolysis correlates with a
larger constitutive level of expression of glycolytic enzymes and a
concomitantly high rate of glycolytic capacity (15).
A significant advance in the understanding of the hypoxic response has
resulted from the recent cloning of the hypoxia inducible transcription
factor HIF-1 (23-25). HIF-1 binds DNA as a dimer composed
of two proteins: a constitutively expressed basic helix-loop-helix (b-HLH) protein, the aryl hydrocarbon nuclear translocator, and an
oxygen-responsive b-HLH protein, HIF-1
. Under normoxic conditions, HIF-1
is rapidly degraded by the ubiquitin-proteasomal pathway, whereas exposure to hypoxia prevents its degradation (9,
18). This increased protein stability results in the
accumulation of nuclear HIF-1
and coincides with a large and
sustained increase in the transcription of genes that contain HIF-1
binding elements (hypoxia response elements) in their control sequences.
The absence of HIF-1
expression causes midgestation lethality in
mice, accompanied by a loss of neural fold closure and decreased capillarization (10, 16). We demonstrated previously that the loss of the HIF-1 response caused an increase in measurable hypoxia
in the embryo, as determined by the redox-responsive bioreductive compound EF5 (16). Furthermore, in situ hybridization
analysis of expression of phosphoglycerate kinase (PGK), an enzyme in
the glycolytic pathway, in wild-type and null embryos demonstrated a
dramatic reduction of expression in null embryos. This demonstrates the
requirement for HIF-1
in the regulation of embryonic expression of
PGK (16). This intriguing result implies that there could be some role for hypoxic response in the regulation of glycolysis during normal development.
To study the effects of loss of HIF-1
postnatally, we created
knock-in mutations in the HIF-1
locus, flanking the second exon
encoding the b-HLH domain with loxP sites. This resulted in
a floxed allele of the gene (17). In short, the procedure creates a conditionally null allele, since the loxP sites
cause the intervening sequence to be deleted in the presence of the cre
recombinase but themselves do not interfere with normal expression (19). The cre recombinase can be expressed either via a
transgene or through the introduction of an expression construct with a viral vector.
The role of hypoxia in stimulating the expression of glycolytic
enzymes, with a concomitant increase in lactic acid production, is well
described in the literature (7). In the presence of glucose, cells adapt to the hypoxic environment in part through increased catabolism of glucose and secretion of lactate. Because of
the accumulation of lactic acid, a physiological hallmark of hypoxia in
tissues is increased acidosis. This creates large decreases in the
intracellular pH, and these are prominent in metabolically active tissues.
Because of the role of hypoxia in modulating metabolic pathways and
because it is clear that HIF-1 is an important mediator of the hypoxic
response, we used conditional targeting of HIF-1
to investigate its
role in the metabolism of hypoxic cells. Deletion of HIF-1
resulted
in major changes in energy metabolism, which in turn affected growth
rates and the production of free ATP during hypoxia. As described
below, these findings demonstrate the important role played by HIF-1
in regulating the metabolism of oxygen-deprived cells.
 |
MATERIALS AND METHODS |
Creation of conditional allele cell lines.
Cell lines were
conditionally targeted via cre-loxP technology at the
HIF-1
locus, as described by Ryan et al. (17). Briefly, experimental cell lines were derived from conditionally targeted mouse
embryonic fibroblasts (mEFs) in which each allele of HIF-1
was
flanked by loxP sites. Cells were then infected with
adenovirus expressing either cre recombinase or
-galactosidase (as a
control for viral infection) to create wild-type (+/+) and nullizygous (
/
) cultures for HIF-1
, respectively. The genotypes of the cultured cells were confirmed by PCR analysis with primers that spanned
the excision event as well as by Southern blot analysis, as described
by Ryan et al. (17). Cells were then immortalized via
simian virus 40 T antigen, followed by transformation with oncogenic
H-ras as described previously (11).
Cell culture.
Unless otherwise noted, fibroblasts were
maintained in 6-cm culture dishes in Dulbecco modified Eagle medium
(DMEM)-high-glucose (4,500 mg of glucose/liter; Life Technologies)
medium supplemented with 10% fetal calf serum and, where relevant, 25 mM HEPES (pH 7.4). Experiments performed in low glucose used the same
DMEM formulation but contained 1,000 mg of glucose per liter. Hypoxic conditions were induced by exposing the cells to 10% CO2
and 0.5 to 1.0% O2, balanced with N2, in a
Sanyo 3-Gas incubator. Unless otherwise noted, all cells were seeded at
a density of 104 per 6-cm dish and allowed to incubate
overnight at normoxia so that the next day corresponded to t = 0.
Growth curves.
Triplicate plates of cells were seeded in
growth medium as described above. The next day, following plating, the
cells were left under normoxia or transferred to the hypoxic chamber,
(t = 0). During these experiments, the cell culture
medium was not changed. Cells were harvested every 24 h by
trypsinization. At least 100 cells from each plate were counted by
hemocytometer, and the average cell number per treatment was
determined. All growth assays described were repeated at least five
times, unless otherwise noted, and the values described in the figures
are representative of one triplicate culture experiment ± the
standard error of the mean (SEM). Where relevant, the glycolytic
inhibitors potassium oxamate (Sigma) or 2-deoxyglucose (Sigma) were
dissolved to a final concentration of 6 mM in DMEM-high-glucose
medium, supplemented with 10% fetal bovine serum (FBS) and 25 mM HEPES
(pH 7.4).
Measurement of lactic acid.
Conditioned medium from
triplicate cultures was harvested and assayed for lactic acid
production via enzymatic colorimetric detection using the Lactic Acid
Assay kit (Sigma) according to the manufacturer's instructions. Values
were normalized to a lactic acid standard curve.
Measurement of cultured cell pH.
Triplicate plates of cells
were cultured in the presence of 3 ml of growth medium. Upon harvest,
the conditioned medium was collected and the pH was determined by using
a Corning pH meter (model 320). During these studies, the medium was
neither changed nor supplemented with HEPES.
Measurement of free ATP: transformed cells.
A constant-light
signal luciferase assay developed by Boehringer-Mannheim (ATP
Bioluminescence Assay Kit CLSII) was utilized to determine levels of
free ATP production during normoxia or hypoxia. Briefly, transformed
wild-type or null cells were seeded in duplicate at 5 × 105 in 6-cm dishes and allowed to incubate overnight. The
next day, the medium was changed, and cells were left at normoxia or
transferred to the hypoxic incubator for 24 to 28 h. Cells were
harvested on ice following two washes with ice-cold phosphate buffered
saline (PBS), scraped into 2 ml of ice-cold PBS, and then spun at
1,000 × g for 10 min at 4°C. Cells were resuspended
at a density of 1 × 106 to 5 × 106
per ml in a 40 mM Tricine buffer (pH 7.75). The diluted cells were
immediately lysed for 5 min at room temperature with the cell lysis
reagent provided, which was supplemented with 1 µg of both aprotinin
and leupeptin per ml. Following lysis, the whole-cell extract was
immediately returned to ice and utilized to measure luciferase activity
within 30 min, according to the manufacturer's instructions. Briefly,
50 µl of luciferase reagent provided in the CLS II kit was added to
50 µl of whole-cell extract and read immediately at 562 nm in a
Lumnistar luminometer at a 2-s integration. In order to normalize the
ATP to cellular protein per sample, the protein content of 50 µl of
each cell extract was determined via a Bradford assay (Bio-Rad)
according to the manufacturer's instructions. The molar amount of ATP
corresponding to each sample was determined based on a log-log plot of
the ATP standards (10
5 to 10
9 M ATP) versus
the relative luciferase units. Next, the molar amount of ATP per
microgram of protein produced by each cell line was determined for each
duplicate plate of cells for each experiment (n = 6 samples/cell line/treatment over the course of three experiments). Following deletion of the highest and lowest statistical outliers, these data (n = 4) were averaged for each cell line,
and the average free ATP values ± the SEM were determined.
Statistical significance was determined by an unpaired t test, wherein
the significance was associated with a P of <0.05.
Primary fibroblasts.
Following mock infection or infection
with adenovirus expressing either
-galactosidase or cre recombinase
as described above, primary cells were seeded overnight at 2 × 105 to 3 × 105 in duplicate 6-cm dishes
and then left at normoxia or transferred to hypoxic conditions for 24 to 28 h (n = 2 per genotype/treatment). Cells from
three independent experiments were harvested and analyzed as described above.
Two-dimensional SDS-PAGE.
To obtain protein samples for
analysis by mass spectrometry, wild-type and HIF-1
-null cells were
plated in DMEM containing 10% FBS (Sigma, St. Louis, Mo.) and 25 mM
HEPES buffer (pH 7.4) at 1.5 × 106
cells/6-cm-diameter plastic culture dish (n = 4/cell
line). After an overnight incubation at 37°C, two dishes for each
cell line were exposed to hypoxia. Defined atmospheric pO2
values were achieved within the range of approximately 1 to
0.01%
(relative to air at a pO2 of ~21%). After exposure to
hypoxia (pO2
0.01%) at 37°C for 18 h, the
chambers were opened in an anaerobic box (Bactron X; Sheldon
Manufacturing, Inc., Cornelius, Oreg.) maintained at 5%
CO2-balance N2 and 37°C. The medium was
removed, and each dish received 2 ml of deoxygenated radioactive
labeling medium. The medium was prepared by adding 35S
labeling solution (East Tag Express [35S]Protein Labeling
Mix; 1,175 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, N.J.) to
cysteine- and methionine-free DMEM (Gibco-BRL/Life Technologies,
Gaithersburg, Md.) containing 10% dialyzed FBS (Gibco-BRL), 25 mM
HEPES (pH 7.4), and 2 mM L-glutamine from a freshly
prepared solution. The final concentration of the 35S label
was 100 µCi/ml. The labeled hypoxic cells were returned to the
aluminium chambers and incubated for 1 h at 37°C before lysis to
obtain the total protein. Aerobic cells were labeled in parallel in 5%
CO2-air at 37°C. To prepare protein from unlabeled aerobic and hypoxic cells, the same protocol was followed except that
the labeling medium contained no 35S-labeled amino acids.
To prepare cells for lysis, the dishes were placed on ice, the medium
was removed, and the cells were washed once with PBS. Cells in each
dish were lysed by adding 400 µl of isoelectric focusing sample
buffer (10 M urea, 2% NP-40, 0.1 M mercaptoethanol, bromophenol blue,
0.25% Pharmalyte pH 3-10 ampholytes; Amersham Pharmacia Biotech) and
scraping. Protein samples (200 µl) were resolved by two-dimensional
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
using the Multiphor II Flatbed Electrophoresis System with 11-cm
Immobiline Drystrip-immobilized pH gradients in the first dimension and
ExcelGel SDS Gradient 8-18 precast gels in the second dimension
(Amersham Pharmacia Biotech) according to the manufacturer's
instructions. The gels were rinsed three times in water to remove the
SDS and then stained overnight with gentle shaking in 0.5% colloidal
Coomassie blue R250 (in acetic acid-isopropanol-water [1:3:6]). The
stained gels were removed from their plastic backing, and those
containing labeled protein were washed briefly in water and then soaked
for 30 min in an autoradiographic signal-enhancing solution containing 1 M sodium salicylate and 2% glycerol. Gels were dried and, if radioactive, exposed to X-Omat X-ray film at
80°C to obtain images of 35S-labeled proteins by autoradiography. Protein spots
for mass spectrometric analysis were identified by comparing the image of a Coomassie blue-stained gel containing unlabeled protein with that
of an autoradiograph of a gel containing 35S-labeled
protein from the same experiment. The fold inductions of
hypoxia-inducible proteins were calculated from electronically scanned
images of the autoradiographs using Melanie II 2-D PAGE image analysis
software (Bio-Rad Laboratories, Richmond, Calif.). Proteins that were
induced by hypoxia, as indicated by an increased incorporation of
label, were excised as fragments from the nonradioactive gels. The gel
fragments were destained by sequential washes in 200 mM ammonium
bicarbonate, methanol-acetic acid (50%:10%), and 40% ethanol. The
proteins in the fragments were reduced in 10 mM dithiothreitol-50 mM
ammonium bicarbonate (pH 8.3) and then alkylated in 55 mM
iodoacetamide-50 mM ammonium bicarbonate (pH 8.3). In-gel tryptic
digestion was performed overnight in 50 mM ammonium bicarbonate (pH
8.3) containing 200ng of trypsin (sequencing grade; Promega Corp.,
Madison, Wis.). After digestion, the fragments were extracted with an
aqueous solution of 5% acetic acid, and the tryptic peptide extracts
were combined and evaporated to dryness using a Savant concentrator.
The peptides were dissolved in 50% methanol and 0.2 or 1% acetic acid
for mass spectral analysis.
Mass spectrometry.
Matrix-assisted laser desorption
ionization-time-of-flight (MALDI-TOF) mass spectra were obtained using
a PerSeptive Biosystems Elite-STR mass spectrometer (Framingham, Mass.)
operated in linear mode. A 1-µl sample of tryptic peptides was mixed
with 2 µl of the MALDI matrix component dihydroxybenzoic acid
(Aldrich Chemical Co., Milwaukee, Wis.) originally prepared as a
saturated solution in 40% aqueous acetonitrile containing 0.1%
trifluoroacetic acid. A 0.5-µl sample of this final solution was
applied to the MALDI target and allowed to evaporate at room
temperature prior to mass spectral analysis. The singly protonated ions
of a standard peptide mixture (PerSeptive Biosystems) were used to
calibrate the mass spectrometer (external calibration).
Nanoelectrospray tandem mass spectrometry (ES-MS-MS) was accomplished
using a Q-Star hybrid quadrupole-TOF instrument (PE/Sciex, Concord,
Ontario, Canada) capable of performing high-resolution and on-line
tandem mass spectrometric experiments. Conventional mass spectra were
obtained by operating the quadrupole in a radio frequency (RF)-only
mode, while a pusher electrode was pulsed (~7-kHz frequency) to
transfer all the ions to the TOF analyzer. Precursor ions for MS-MS
analysis were selected by the first quadrupole, while a pusher
electrode was pulsed (~7-kHz frequency) to transfer fragment ions
formed in the RF-only quadrupole cell to the TOF analyzer. The mass
spectral resolution was typically 9,000 to 10,000 (at peak half
height). Scan durations of 1 and 2 s were set for conventional and
MS-MS mass spectral acquisition, respectively. Collisional activation
was achieved by using an N2 or Ar collision gas with a 45-V
offset between the DC voltage of the entrance quadrupole and the
RF-only quadrupole cell.
Database searching with mass spectrometric data.
Peptide
masses were determined using external standardization of the MALDI-TOF
instrument, and the mass data were transferred to the PeptideSearch
program. The list of peptide masses was searched against a nonredundant
protein sequence database containing over 257,000 entries downloaded
from the European Bioinformatics Institute website
(ftp://ftp.ebi.ac.uk/pub/databases/peptidesearch/). Parameters for all
searches assumed that masses corresponded to tryptic peptides and that
cysteines residues were converted to
S-(carbamidomethyl)cysteine. All peptide masses were
considered monoisotopic, and the maximum deviation between the
calculated and measured masses was set to <50 ppm. The searches did
not impose any restrictions on the species of origin, and the range of
protein masses was set to 0 to 300 kDa. Alternatively, searches were
conducted using the peptide sequence tag approach, wherein the precise
molecular mass of a given tryptic peptide plus a partial amino acid
sequence derived from its MS-MS spectrum were used.
 |
RESULTS |
Cells lacking HIF-1
exhibit a reduced rate of growth in response
to hypoxia.
Recent data from our laboratory demonstrated that
tumors derived from transformed HIF-1
-null fibroblasts created via
cre-loxP recombinase-mediated deletion of HIF-1
were
smaller than those derived from wild-type cells (17).
Curiously, the relative vascular density was similar in these two tumor
types (17). Because this finding implied that some other
mechanism of transformed cell growth was deficient in cells lacking
HIF-1
, we began to evaluate other likely deficiencies in the ability
of HIF-1
-null cells to withstand hypoxia.
As seen in Fig. 1A, exponential-phase
cells lacking HIF-1
were able to grow at approximately the same rate
as wild-type controls (+/+) under normoxic conditions. However, as seen
in Fig. 1B, growth of the cells in the exponential phase of culture
under hypoxia was limited by the loss of HIF-1
expression. Since the loss of HIF-1
expression first becomes evident in log-phase growth, the defect is most likely a deficiency in proliferative capacity, since
such differences are most evident during periods of rapid growth.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Growth of HIF-1 -null cells is reduced during hypoxia
but not during normoxia. Following overnight seeding at a low density,
cells were incubated in normoxic (A) or hypoxic (B) conditions in
high-glucose medium and harvested every 24 h until the cultures
reached confluence. The average cell number of triplicate plates for
each condition ± the SEM was determined by counting by
hemacytometer following trypsinization. The maximal difference in
growth rates between wild-type (+/+) ( ) and HIF-1 -null ( / )
( ) cells is noted during hypoxia at 72 h posthypoxia.
|
|
Altered rates of HIF-1
-dependent growth in hypoxia are affected
by glucose levels.
In order to investigate the deficiency in
HIF-1
-null cell growth during hypoxia, we began by determining
whether cell growth was affected by the availability of glucose.
Specifically, this study was done to investigate the relationship
between energy metabolism during hypoxia and glucose utilization in the
presence and absence of HIF-1
. Consistent with the growth curves
shown in Fig. 1 and 2A, our studies
indicate that, 72 h after the initiation of hypoxia (at which a
divergence in cell growth became clearly evident between the wild-type
and null cells), there was a large difference in cell numbers between
the HIF-1
wild-type cell cultures and the null cell cultures that
was not observed at normoxia. However, the results presented in Fig. 2B
demonstrate that these differences in cell growth could be eliminated
by lowering the glucose concentration of the medium by approximately
4.5-fold. This observation indicates that cells lacking HIF-1
show
deficiencies in growth during hypoxia compared to wild-type cells only
when glucose uptake and/or consumption is not limiting. Together, these findings imply that the deficiency in cell growth during hypoxia caused
by loss of HIF-1
expression is related to glucose metabolism.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
During hypoxia, growth rate of wild-type cells, but not
null cells, is dependent on glucose availability. Triplicate plates of
cells were cultured in either high-glucose (4,500-mg/ml) (A) or
low-glucose (1,000-mg/ml) (B) DMEM at normoxia (solid bars) or hypoxia
(striped bars), and the cell count ± the SEM was determined at
72 h following trypsinization by using a hemacytometer. The loss
of HIF-1 does not affect growth at normoxia under high- or
low-glucose conditions. In addition, at hypoxia, the availability of
glucose does not affect the growth rate of the null cells since the
number of cells present is approximately the same whether cells are
cultured in high- or low-glucose medium (compare panels A and B).
However, during hypoxia there is a significant difference in cell
density between wild-type cells and null cells cultured in high glucose
due to the increased growth of wild-type cells in high-glucose medium
(compare panels A and B).
|
|
Loss of HIF-1
eliminates increased lactate production during
hypoxia.
A classically studied feature of hypoxic cell growth is
the increased production of lactic acid caused by continuous conversion of pyruvate to lactate (26). To further determine the
relationship between HIF-1
function, glucose metabolism, and cell
growth, we assayed the levels of lactic acid created during normoxic
and hypoxic exposures of wild-type and HIF-1
-null cells. As shown in
Fig. 3, when the results were adjusted to
account for the cell number, there was no difference in lactate
production during normoxia between HIF-1
wild-type and null cells.
However, the typical rise of lactate production found in wild-type cell
cultures during hypoxia was absent in HIF-1
-null cells grown under
the same conditions. This finding provides further evidence of an
alteration in the utilization of glucose during hypoxia in cells
lacking HIF-1
activity.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Lactate production is decreased in HIF-1 -null cells
during prolonged culture at hypoxia. Following seeding at low density
and overnight plating in high-glucose, phenol red-free DMEM,
conditioned medium was collected from triplicate plates of wild-type or
null cells cultured at normoxia or hypoxia and utilized to determine
lactate by a colorimetric enzyme assay. Values obtained from the
conditioned medium were normalized to a lactate standard curve. A
representative graph of a typical experiment is shown ± the SEM
of the triplicate values. Significant increases in lactate production
are noted in the wild-type cells during prolonged cultured at hypoxia;
however, null cells produced lactate at similar levels to those
produced by wild-type cells cultured at normoxia. Symbols: , +/+
(normoxia); , / (normoxia); , +/+ (hypoxia); , /
(hypoxia).
|
|
Altered pH profiles of hypoxic cultures lacking HIF-1
.
Acidosis is a hallmark of tumor physiology and is primarily caused by
lactate production in transformed tissue (7). To determine
whether the loss of HIF-1
expression and the associated change in
lactic acid production altered the rate of acidosis during exposure to
prolonged hypoxia, extracellular pH was measured as a function of time
under hypoxia in cultures of wild-type and of HIF-1
-null cells. As
shown in Fig. 4, there was a
glucose-dependent drop in pH that was dependent on the presence or
absence of HIF-1
.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
Acidosis does not occur in HIF-1 -null cells following
prolonged culture in high glucose at hypoxia. Wild-type and null cells
were seeded at low density in either DMEM containing high (A and B) or
low (C and D) glucose and allowed to plate overnight. Conditioned
medium (3 ml) was collected from triplicate plates every 24 h
after incubation at normoxia or hypoxia. Immediately upon harvesting,
the pH of the conditioned medium was determined by using a Corning pH
meter. A representative graph of a typical experiment is shown ± the SEM. When cells were cultured in low-glucose medium, the pH of the
conditioned medium is similar when harvested from either wild-type
cells or null cells at normoxia (C) and hypoxia (D), and the pH falls
within normal physiological levels (pH 7.2 to 7.4). In contrast, when
wild-type and null cells cultured in high glucose at hypoxia are
compared (B), there is a significant decrease in pH that occurs in the
wild-type cells (pH ~6.7) versus null cells (pH ~7.3). The timing
of this decrease correlates with the period of time for which the
maximal differences in both growth rate and lactate production have
been previously demonstrated. When cultured in high-glucose medium at
normoxia (A), there is no significant difference in the pH values
between wild-type and null cells, although the pH decreases to a more
significant extent in both cell lines compared to the same cells grown
in low glucose (C). Symbols: , +/+; , / .
|
|
Buffering increases the growth of wild-type cells, but not
HIF-1
-null cells, during hypoxia.
Hypoxic alterations in pH
have been reported to affect the growth rate of cells in culture
(20). In order to determine what effect increased acidosis
had on the growth rate of cells under hypoxia (Fig. 1), cells were
incubated during normoxia and hypoxia in medium buffered with 25 mM
HEPES to maintain a neutral pH. As shown in Fig.
5A, this buffer produced a significant
boost to the late log phase growth of wild type cells during hypoxia. This finding indicates that for wild-type cells increased culture acidity influences cell growth. However, as seen in Fig. 5B,
HIF-1
-null cells were unaffected by buffering since the growth rate
with or without HEPES supplementation was still lower than the hypoxic growth rate of wild-type cells in either medium. These findings indicate that, although acidosis in culture causes some degree of
growth inhibition of wild-type cells, it does not affect the growth of
HIF-1
-null cells. In principle, this response to extracellular acidity could allow HIF-1
to act in some circumstances as a negative factor in tumor growth. However, as shown in Fig. 5A, differential accumulation of lactate and the resulting acidosis of wild-type hypoxic
cultures was ultimately not enough to compensate for the pH-independent
defects in HIF-1
-null cell growth during hypoxia.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Buffering of culture medium increases the growth of
wild-type cells, but not null cells, during the late log phase of
growth during prolonged culture at hypoxia. The growth rate of
wild-type (A) and HIF-1 -null (B) cells cultured in high-glucose DMEM
with or without supplementation with 25 mM (final concentration) HEPES
buffer (pH 7.4) was compared at hypoxia over time. Buffering the medium
had no effect on HIF-1 -null cells (see panel B) but significantly
enhanced the late log phase of growth in wild-type cells between 72 and
120 h at hypoxia. Symbols: , +/+; , +/+ (HEPES); , / ;
, / (HEPES).
|
|
Free ATP levels are dramatically reduced during hypoxic growth in
the absence of HIF-1
.
To assay for changes in cellular energy
metabolism in response to hypoxic stress, ATP production by the
transformed cell lines was quantified under normoxia and hypoxia as a
function of time. These assays indicated that the levels of total
cellular ATP began to decrease in HIF-1
-null cells compared to
wild-type cells by 8 h of hypoxia, with a maximal level of
decrease by 24 h of stress (data not shown). Because free ATP
levels did not decrease significantly further during the period from 24 to 96 h of hypoxia, we chose 24 h as the time point to
complete these studies. In order to compare the levels of ATP in
transformed cells under normoxia or hypoxia, whole-cell extracts were
prepared. Subsequently, the molar amount of free ATP produced by each
cell line was normalized for protein levels within each whole-cell
lysate. As shown in Fig. 6, the total
amounts of free ATP produced during hypoxia were dependent on the
HIF-1
status of the cells. Under hypoxia, the levels of free ATP in
HIF-1
-null cells were approximately half of those observed for the
wild-type cells. To determine whether this observation held true for
primary as well as transformed, immortalized cells, we performed the
same assay on primary fibroblasts lacking HIF-1
. Figure
7 shows that the results for total
cellular ATP levels in primary cells paralleled those obtained for the transformed cell lines, clearly demonstrating that HIF-1
-null primary cells were also unable to maintain normal levels of ATP during
prolonged periods of hypoxia. Curiously, we found that primary, but not
transformed, wild-type cells increased their free ATP levels when the
glucose level was not limiting. This increased level of free ATP was
always seen in primary mEFs, although it is absent in HIF-1
-null
cells, and may represent a compensatory response to hypoxia in these
cells. Importantly, it is still the case that the shift under hypoxia
remains HIF-1
dependent.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
Free ATP levels are decreased in HIF-1 -null cells by
approximately half at hypoxia. Following seeding at high density
(5 × 105) and plating overnight, cells cultured in
DMEM-high-glucose medium supplemented with 25 mM HEPES were left at
normoxia or transferred to a hypoxia chamber for 24 to 28 h. The
levels of free ATP were estimated based on the ATP-dependent luciferase
activity present in whole-cell extracts as described in Materials and
Methods. To normalize for differences in cell number between wild-type
and null cells, the molar levels of free ATP were corrected for the
levels of protein (in micrograms) present in the same cell extracts
prepared for the luciferase assay. This graph represents the results of
the average of three independent assays (± the SEM) minus the highest
and lowest outlying datum points for each genotype, as described in the
Materials and Methods (n = 4 per treatment/genotype).
At normoxia (solid bars), the molar ATP levels per microgram of protein
tended to be more variable in null cells than in wild-type cells, but
there was no statistical significance in ATP production between either
genotype. In contrast, at hypoxia (hatched bars), the levels of free
ATP produced by null cells was approximately half of that produced by
wild type cells and represented a statistically significant
difference.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 7.
The decrease of free ATP levels in HIF-1 null primary
fibroblasts parallels that observed in transformed null cells.
Following infection with -galactosidase or cre adenovirus, primary
mEFs were seeded at 2 × 105 to 3 × 105 in DMEM-high-glucose medium supplemented with 25 mM
HEPES (pH 7.4). The next day, the cells were left at normoxia or were
transferred to hypoxia for 24 h. Cell extracts were prepared and
normalized as described in Materials and Methods. At normoxia (solid
bars) there was no statistically significant difference in the levels
of free ATP production in wild-type or null cells. However, at hypoxia
(hatched bars) the decrease in the levels of free ATP produced by null
cells was approximately 50%, paralleling the decrease observed in
transformed cells as shown in Fig. 6. Therefore, the effect of loss of
HIF-1 on cellular metabolism is consistent in both normal and
transformed cells.
|
|
Effect of glycolytic inhibitors on cell growth.
In order to
determine whether altered glycolytic rates affect the cell growth of
the transformed cell populations utilized in these sets of experiments,
we employed two different glycolytic inhibitors, oxamic acid and
2-deoxyglucose, that act on different aspects of the glycolytic pathway
(8). Growth rates were compared during hypoxia to
determine whether the effects of the inhibitors on the cell growth of
wild-type cells were similar to those caused by the absence of
HIF-1
. As seen in Fig. 8, at 24 h
both drugs reduce the rate of wild-type cell growth during hypoxia to
an extent similar to that seen following the loss of HIF-1
. This observation demonstrates that, in our system, the inhibition of glycolysis in hypoxic conditions reduces the rate of cell growth.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 8.
The growth rate of wild-type cells treated with
glycolytic inhibitors parallels the growth rate observed in
HIF-1 -null cells. Following seeding at moderate density (2 × 105) and plating overnight, cells were washed once with PBS
and then cultured in DMEM-high-glucose medium supplemented with 25 mM
HEPES (pH 7.4) containing either no drug (NO), 6 mM oxamate (OX), or 6 mM 2-deoxyglucose (2-DEOXY). After 24 h of incubation at hypoxia,
triplicate plates of cells per treatment were harvested by
trypsinization and counted by using a hemacytometer. This graph is
representative of the changes in growth rates ± the SEM observed
in three independent experiments. Treatment of wild-type cells with
either oxamate or 2-deoxyglucose reduces the growth of wild-type cells
to levels similar to those observed in cells deleted for HIF-1 ,
indicating that the proper regulation of glycolysis is required for
maximal cell growth during hypoxia.
|
|
Proteome profilling of HIF-1
wild-type cells versus
HIF-1
-null cells demonstrates the predominance of glycolytic enzymes
among proteins regulated by HIF-1 expression.
A number of groups
have shown that the loss of HIF-1
expression results in decreased
transcriptional induction of glycolytic enzymes as well as that of
other genes (5, 6, 10, 13, 14, 16, 17; for a review, see
reference 3). However, transcript levels can differ from
the levels of the corresponding proteins because of differential rates
of protein translation and differences in protein turnover and/or
stability. This is in fact the case for HIF-1
(9, 18).
Therefore, in order to better understand the proteomic alterations
caused by lowered oxygen levels, we investigated the
hypoxia-responsive, global protein expression pattern dependent on the
presence of HIF-1
. This analysis was accomplished through
two-dimensional SDS-PAGE resolution of extracts prepared from cells
that were either HIF-1
wild type (containing a floxed allele of
HIF-1
) or HIF-1
null (following cre recombinase-mediated excision
of the HIF-1
allele) (Fig. 9). These
cells were placed in normoxic or hypoxic environments for 18 h, at
which point radioactively labeled proteins were extracted and resolved.
Proteins that exhibited significant HIF-1
-dependent variation were
excised and subsequently identified by mass spectrometry. These
analyses revealed that the three most significant changes in
HIF-1
-dependent protein expression found within the pI range of ca.
3 to 10 were inductions of the glycolytic enzymes PGK-1, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and triose phosphate isomerase (TPI). The fold inductions of these three enzymes are given
in Table 1. These inductions were typical
of those seen for these spots in at least two independent experiments
and indicate that the loss of HIF-1
alters the levels of protein
expression of multiple glycolytic enzymes.

View larger version (88K):
[in this window]
[in a new window]
|
FIG. 9.
Two-dimensional gel autoradiographs indicate that the
majority of differences in the HIF-1 proteome can be identified as
glycolytic enzymes. Representative autoradiographs of two-dimensional
SDS-PAGE gradient gels are presented showing labeled total protein from
wild-type and HIF-1 -null mEFs exposed to 18 h of hypoxia
(pO2 0.01%, relative to air at a pO2
of ~21%). Cells were labeled under aerobic or anaerobic conditions
for 1 h (35S-labeled cysteine and methionine at 100 µCi/ml, 37°C). Spots are labeled with both the original
identification number and their protein assignment by mass
spectrometric analysis. CPH, cyclophilin (unchanged); HSP70, heat shock
protein 70 (unchanged); PGK, induced in wild-type cells only; TPI,
induced in wild-type cells only; GAPDH, induced in wild-type cells
only.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Tryptic peptide assignments from ES-MS-MS analyses of
proteins from wild-type and HIF-1 -null mEFs resolved by denaturing
two-dimensional PAGE
|
|
 |
DISCUSSION |
It is a long-standing observation that decreased oxygenation of
animal cells forces an increased reliance on glycolysis for ATP
production. Using genetically manipulated cells, we demonstrate a
critical requirement for the transcription factor HIF-1 in controlling this shift to glycolysis (the Pasteur effect). We argue that HIF-1 is a
critical integrator of cellular adaptation to hypoxia because, in the
absence of HIF-1
, otherwise genetically identical cells show
physiologically significant alterations in energy metabolism. We
hypothesize that reduced ATP levels may cause cell growth deficiencies in HIF-1
-null cells, and suggest that a universal mechanism for the
control of hypoxic response during metabolism is activation of the
HIF-1 regulated pathway. Although the topic is not directly addressed
in these studies, it is likely that HIF-1, because of its role in
regulating glycolysis, is also a primary mediator of the Warburg
effect, in which tumor cells show increased glycolytic activity even
under physiological oxygen conditions (25). Presumably, the Warburg effect is contingent on the deregulation of normal controls
for the expression and activity of HIF-1.
It was necessary to begin our efforts with a survey of the effects on
cell growth in cell lines from which HIF-1
expression had been
eliminated. The cre-loxP system presents a very useful technology for this sort of study in cell culture because it avoids long-term passaging in the absence of a specific necessary gene; such
culture can give rise to compensating mutations or alterations in gene
expression. Our experiments involved the immortalization and culture of
cells and then adenoviral excision of the relevant locus immediately
prior to assays of the phenotype, thus decreasing the likelihood of
cultured cells diverging through culture alone to compensate for the
absence of the targeted gene.
Our first survey of HIF-1
-null cells showed that they were deficient
in growth during hypoxia relative to wild-type cells. In contrast, this
deficiency was not present when the HIF-1
-null cells were cultured
in hypoxia with lowered amounts of glucose. These findings indicated
that the loss of HIF-1
expression altered the ability of the cells
to grow in a glucose-dependent fashion. HIF-1
controls the
hypoxically induced expression of the glucose transporter GLUT-1;
therefore, it may be the case that altered rates of glucose uptake are
involved in the reduced growth rates of these cells under hypoxia.
Interestingly, HIF-1 is also involved in IGF-1 signaling
(27). How HIF-1 controls energy metabolism in cases of
hypoglycemia remains to be determined.
We found that the decreased levels of glycolytic enzymes were
correlated with a diminished enzymatic activity in HIF-1
-null cells,
evidenced by a greatly reduced rate of lactate accumulation in the
conditioned medium of these cells. Lactate is the main contributor to
acidosis, a hallmark of hypoxic tissues and many solid tumors. Changes
in intracellular pH, in turn, are likely to have dramatic effects on
the rates of cell growth and apoptosis. A number of reports have shown
that the absence of HIF-1
has significant effects on the rates of
tumor growth, with one group describing an increased rate of tumor
growth in the absence of HIF-1 (2). We have been unable to
confirm such an increase in cell growth in our own experiments
conducted with HIF-1
-deficient cells (16, 17).
Nonetheless, it is clear from our findings that one definite advantage
that HIF-1
-null cells have over wild-type cells in a hypoxic
environment is a decreased lactate secretion rate. This difference
could in turn have very significant effects on the survival and growth
of tumors; it also may point to HIF-1
-dependent effects on acidosis
in other tissues during hypoxia. Tissues particularly susceptible to
hypoxic injury, such as those of the nervous system, are also
susceptible to changes in cellular pH, and alterations in HIF-1
activity may provide a system to alleviate such changes.
As a measure of the output of the glycolytic pathway, an important,
albeit complex, readout is the actual amount of free ATP produced in
the cell. This measurement becomes slightly less complex during
hypoxia, because the hypoxic state suppresses the mitochondrial contribution to the pool of cellular free ATP. Under hypoxic
conditions, we found that HIF-1
is a critical regulator of the
maintenance of free ATP levels in both transformed and primary cells.
In cells lacking HIF-1
, free ATP levels during hypoxic culture were
reduced by half, falling to this level in approximately 8 to 16 h
and remaining at these reduced levels during extended culture of the cells in hypoxic conditions. Presumably, the loss of HIF-1 activity eliminates the inducible component but not the basal component of the
transcriptional response of the glycolytic pathway to hypoxia or
anoxia, decreasing but not eliminating the production of ATP.
Interestingly, although the HIF-1-related change in ATP levels occurs
in both transformed and primary cells during hypoxia, in primary cells
this change is complicated by the large increase in ATP levels during
the hypoxic state. This is likely due to the relative hyperglycemia of
tissue culture medium and an efficient usage of it under hypoxic
conditions; it is clear, however, that the hypoxia-induced shift is
still HIF-1
dependent. Thus, HIF-1
-dependent regulation of free
ATP appears to be a conserved mechanism for the cell to regulate the
metabolic response to hypoxic conditions. Furthermore, these results
clearly demonstrate the need for a transcriptional response to alter
the metabolic activity of the cell. What is perhaps surprising is that
this critical parameter of energy metabolism should be regulated so
effectively by one transcription factor.
Although a number of surveys of transcriptional alterations in response
to hypoxia have been done, no assays of HIF-1-induced changes in
protein levels have previously been attempted. We began to characterize
the changes in global protein expression during hypoxia in wild-type
and null cells to determine the overall profile of changes controlled
at the proteomic level by HIF-1
. Our initial results have clearly
shown that some of the most prominent changes in protein expression
occur in enzymes within the glycolytic pathway. It is important to
recognize that these HIF-1
-dependent, hypoxia-inducible proteins
were selected for mass spectrometry analysis based not only on the
criterion that they are clearly detected by pulse 35S
labeling but also on the criterion that they be detected by Coomassie
blue staining. Thus, these proteins were present in nanogram quantities
in the total cell lysates. Less-abundant HIF-1
-dependent and
hypoxia-inducible proteins were not investigated in these studies.
Nevertheless, the significant inductions at the protein level of these
already-abundant proteins indicate that changes in the protein
expression of critical glycolytic enzymes are a salient feature of the
response of the mEF proteome to this degree of hypoxia or anoxia. These
HIF-1
-dependent changes at the proteomic level include enzymes
located throughout the glycolytic pathway. This fundamental observation
stands in contrast to classical notions of a small number of
rate-limiting enzymes controlling the activity of the glycolytic
pathway. Our results, however, coincide with the hypothesis of Fell
that metabolism is broadly controlled at many stages, allowing for
maximum pliability and responsiveness of controlled catabolism
(4).
There are likely to be pleiotropic consequences of HIF-1
regulation
of energy metabolism: cell cycle progression and apoptosis, among other
processes, have numerous ATP-dependent components. Further study is
required to elucidate the specific role for HIF-1 in the regulation of
these downstream aspects of metabolism. How these cellular processes in
turn interact with the hypoxic regulation of metabolism will facilitate
more in-depth evaluation of how intercession in the hypoxic response
may provide therapies for a range of pathological conditions.
 |
ACKNOWLEDGMENTS |
T.N.S. and H.E.R. contributed equally to this work.
T.N.S. is supported by NIH/NCI National Research Service Award T32
CA09523 and the Susan G. Komen Breast Cancer Foundation. K.L. is
supported by grants CA67166, CA73807, and MOP36481. R.S.J. is supported
by NIH grant CA82515.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Biology, University of California, San Diego, 1212 Pacific Hall, Mail
code 0366, 9500 Gilman Dr., La Jolla, CA 92093. Phone: (858) 822-0509. Fax: (858) 534-5831. E-mail: rjohnson{at}biomail.ucsd.edu.
 |
REFERENCES |
| 1.
|
Brown, J. M., and A. J. Giaccia.
1998.
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Cancer Res.
58:1408-1416[Abstract/Free Full Text].
|
| 2.
|
Carmeliet, P.,
Y. Dor,
J. M. Herbert,
D. Fukumura,
K. Brusselmans,
M. Dewerchin,
M. Neeman,
F. Bono,
R. Abramovitch,
P. Maxwell,
C. J. Koch,
P. Ratcliffe,
L. Moons,
R. K. Jain,
D. Collen, and E. Keshet.
1998.
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature
394:485-490[CrossRef][Medline].
|
| 3.
|
Ebert, B. L., and H. F. Bunn.
1999.
Regulation of the erythropoietin gene.
Blood
94:1864-1877[Free Full Text].
|
| 4.
|
Fell, D.
1997.
Understanding the control of metabolism.
Portland Press/Ashgate Publishing Co., Brookfield, Vt.
|
| 5.
|
Firth, J. D.,
B. L. Ebert,
C. W. Pugh, and P. J. Ratcliffe.
1994.
Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer.
Proc. Nat. Acad. Sci. USA
91:6496-6500[Abstract/Free Full Text].
|
| 6.
|
Firth, J. D.,
B. L. Ebert, and P. J. Ratcliffe.
1995.
Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements.
J. Biol. Chem.
270:21021-21027[Abstract/Free Full Text].
|
| 7.
|
Gillies, R. J.,
P. A. Schornack,
T. W. Secomb, and N. Raghunand.
1999.
Causes and effects of heterogeneous perfusion in tumors.
Neoplasia
1:197-207[CrossRef][Medline].
|
| 8.
|
Hamilton, E.,
M. Fennell, and D. M. Stafford.
1995.
Modification of tumour glucose metabolism for therapeutic benefit.
Acta Oncologica
34:429-433[Medline].
|
| 9.
|
Huang, L. E.,
J. Gu,
M. Schau, and H. F. Bunn.
1998.
Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.
Proc. Nat. Acad. Sci. USA.
95:7987-7992[Abstract/Free Full Text].
|
| 10.
|
Iyer, N. V.,
L. E. Kotch,
F. Agani,
S. W. Leung,
E. Laughner,
R. H. Wenger,
M. Gassmann,
J. D. Gearhart,
A. M. Lawler,
A. Y. Yu, and G. L. Semenza.
1998.
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha.
Genes Dev.
12:149-162[Abstract/Free Full Text].
|
| 11.
|
Johnson, R.,
B. Spiegelman,
D. Hanahan, and R. Wisdom.
1996.
Cellular transformation and malignancy induced by ras require c-Jun.
Mol. Cell. Biol.
16:4504-4511[Abstract].
|
| 12.
|
Lehninger, A. L.,
M. M. Cox, and D. L. Nelson.
1993.
Principles of biochemistry, 2nd ed.
Worth Publishers, New York, N.Y.
|
| 13.
|
Maxwell, P. H.,
G. U. Dachs,
J. M. Gleadle,
L. G. Nicholls,
A. L. Harris,
I. J. Stratford,
O. Hankinson,
C. W. Pugh, and P. J. Ratcliffe.
1997.
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.
Proc. Natl. Acad. Sci. USA
94:8104-8109[Abstract/Free Full Text].
|
| 14.
|
O'Rourke, J. F.,
C. W. Pugh,
S. M. Bartlett, and P. J. Ratcliffe.
1996.
Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1.
Eur. J. Biochem.
241:403-410[Medline].
|
| 15.
|
Rodríguez-Enríquez, S., and R. Moreno-Sánchez.
1998.
Intermediary metabolism of fast-growth tumor cells.
Arch. Med. Res.
29:1-12[Medline].
|
| 16.
|
Ryan, H.,
J. Lo, and R. S. Johnson.
1998.
The hypoxia inducible factor-1 alpha gene is required for embryogenesis and solid tumor formation.
EMBO J.
17:3005-3015[CrossRef][Medline].
|
| 17.
|
Ryan, H. E.,
M. Poloni,
W. McNulty,
D. Elson,
M. Gassmann,
J. M. Arbeit, and R. S. Johnson.
2000.
Hypoxia-inducible factor-1 alpha is a positive factor in solid tumor growth.
Cancer Res.
60:4010-4015[Abstract/Free Full Text].
|
| 18.
|
Salceda, S., and J. Caro.
1997.
Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.
J. Biol. Chem.
272:22642-22647[Abstract/Free Full Text].
|
| 19.
|
Sauer, B., and N. Henderson.
1990.
Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase.
New Biol.
2:441-449[Medline].
|
| 20.
|
Schmaltz, C.,
P. H. Hardenbergh,
A. Wells, and D. E. Fisher.
1998.
Regulation of proliferation-survival decisions during tumor cell hypoxia.
Mol. Cell. Biol.
18:2845-2854[Abstract/Free Full Text].
|
| 21.
|
Semenza, G. L.
1998.
Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis.
J. Lab. Clin. Med.
131:207-214[CrossRef][Medline].
|
| 22.
|
Stryer, L.
1995.
Biochemistry, 4th ed.
W. H. Freeman, New York, N.Y.
|
| 23.
|
Wang, G. L., and G. L. Semenza.
1993.
Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
J. Biol. Chem.
268:21513-21518[Abstract/Free Full Text].
|
| 24.
|
Wang, G. L., and G. L. Semenza.
1993.
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Proc. Natl. Acad. Sci. USA
90:4304-4308[Abstract/Free Full Text].
|
| 25.
|
Wang, G. L., and G. L. Semenza.
1995.
Purification and characterization of hypoxia-inducible factor 1.
J. Biol. Chem.
270:1230-1237[Abstract/Free Full Text].
|
| 26.
|
Warburg, O. H.
1947.
Ideen zur Fermentchemic der Tumoren.
Akademie-Verlag, Berlin, Germany.
|
| 27.
|
Zelzer, E.,
Y. Levy,
C. Kahana,
B. Z. Shilo,
M. Rubinstein, and B. Cohen.
1998.
Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT.
EMBO J.
17:5085-5094[CrossRef][Medline].
|
Molecular and Cellular Biology, May 2001, p. 3436-3444, Vol. 21, No. 10
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.10.3436-3444.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Walczak-Drzewiecka, A., Ratajewski, M., Wagner, W., Dastych, J.
(2008). HIF-1{alpha} Is Up-Regulated in Activated Mast Cells by a Process That Involves Calcineurin and NFAT. J. Immunol.
181: 1665-1672
[Abstract]
[Full Text]
-
Gillies, R. J., Robey, I., Gatenby, R. A.
(2008). Causes and Consequences of Increased Glucose Metabolism of Cancers. JNM
49: 24S-42S
[Abstract]
[Full Text]
-
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., Semenza, G. L.
(2008). Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia. J. Biol. Chem.
283: 10892-10903
[Abstract]
[Full Text]
-
Jantsch, J., Chakravortty, D., Turza, N., Prechtel, A. T., Buchholz, B., Gerlach, R. G., Volke, M., Glasner, J., Warnecke, C., Wiesener, M. S., Eckardt, K.-U., Steinkasserer, A., Hensel, M., Willam, C.
(2008). Hypoxia and Hypoxia-Inducible Factor-1{alpha} Modulate Lipopolysaccharide-Induced Dendritic Cell Activation and Function. J. Immunol.
180: 4697-4705
[Abstract]
[Full Text]
-
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., Powis, G.
(2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1{alpha}. Molecular Cancer Therapeutics
7: 90-100
[Abstract]
[Full Text]
-
Mason, S. D., Rundqvist, H., Papandreou, I., Duh, R., McNulty, W. J., Howlett, R. A., Olfert, I. M., Sundberg, C. J., Denko, N. C., Poellinger, L., Johnson, R. S.
(2007). HIF-1{alpha} in endurance training: suppression of oxidative metabolism. Am. J. Physiol. Regul. Integr. Comp. Physiol.
293: R2059-R2069
[Abstract]
[Full Text]
-
Cai, Q., Murakami, M., Si, H., Robertson, E. S.
(2007). A Potential {alpha}-Helix Motif in the Amino Terminus of LANA Encoded by Kaposi's Sarcoma-Associated Herpesvirus Is Critical for Nuclear Accumulation of HIF-1{alpha} in Normoxia. J. Virol.
81: 10413-10423
[Abstract]
[Full Text]
-
Hoogewijs, D., Terwilliger, N. B., Webster, K. A., Powell-Coffman, J. A., Tokishita, S., Yamagata, H., Hankeln, T., Burmester, T., Rytkonen, K. T., Nikinmaa, M., Abele, D., Heise, K., Lucassen, M., Fandrey, J., Maxwell, P. H., Pahlman, S., Gorr, T. A.
(2007). From critters to cancers: bridging comparative and clinical research on oxygen sensing, HIF signaling, and adaptations towards hypoxia. Integr. Comp. Biol.
47: 552-577
[Abstract]
[Full Text]
-
Mizukami, Y., Kohgo, Y., Chung, D. C.
(2007). Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis. Clin. Cancer Res.
13: 5670-5674
[Abstract]
[Full Text]
-
Dehne, N., Kerkweg, U., Otto, T., Fandrey, J.
(2007). The HIF-1 response to simulated ischemia in mouse skeletal muscle cells neither enhances glycolysis nor prevents myotube cell death. Am. J. Physiol. Regul. Integr. Comp. Physiol.
293: R1693-R1701
[Abstract]
[Full Text]
-
Agrawal, A., Guttapalli, A., Narayan, S., Albert, T. J., Shapiro, I. M., Risbud, M. V.
(2007). Normoxic stabilization of HIF-1{alpha} drives glycolytic metabolism and regulates aggrecan gene expression in nucleus pulposus cells of the rat intervertebral disk. Am. J. Physiol. Cell Physiol.
293: C621-C631
[Abstract]
[Full Text]
-
Cairns, R. A., Papandreou, I., Sutphin, P. D., Denko, N. C.
(2007). Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc. Natl. Acad. Sci. USA
104: 9445-9450
[Abstract]
[Full Text]
-
Lum, J. J., Bui, T., Gruber, M., Gordan, J. D., DeBerardinis, R. J., Covello, K. L., Simon, M. C., Thompson, C. B.
(2007). The transcription factor HIF-1{alpha} plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev.
21: 1037-1049
[Abstract]
[Full Text]
-
Gruber, M., Hu, C.-J., Johnson, R. S., Brown, E. J., Keith, B., Simon, M. C.
(2007). Acute postnatal ablation of Hif-2{alpha} results in anemia. Proc. Natl. Acad. Sci. USA
104: 2301-2306
[Abstract]
[Full Text]
-
Maher, J. C., Wangpaichitr, M., Savaraj, N., Kurtoglu, M., Lampidis, T. J.
(2007). Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Molecular Cancer Therapeutics
6: 732-741
[Abstract]
[Full Text]
-
Liao, D., Corle, C., Seagroves, T. N., Johnson, R. S.
(2007). Hypoxia-Inducible Factor-1{alpha} Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression. Cancer Res.
67: 563-572
[Abstract]
[Full Text]
-
Lopez-Lazaro, M.
(2006). Hypoxia-Inducible Factor 1 as a Possible Target for Cancer Chemoprevention. Cancer Epidemiol. Biomarkers Prev.
15: 2332-2335
[Abstract]
[Full Text]
-
Choi, S. M., Choi, K.-O., Park, Y.-K., Cho, H., Yang, E. G., Park, H.
(2006). Clioquinol, a Cu(II)/Zn(II) Chelator, Inhibits Both Ubiquitination and Asparagine Hydroxylation of Hypoxia-inducible Factor-1{alpha}, Leading to Expression of Vascular Endothelial Growth Factor and Erythropoietin in Normoxic Cells. J. Biol. Chem.
281: 34056-34063
[Abstract]
[Full Text]
-
Ke, Q., Costa, M.
(2006). Hypoxia-Inducible Factor-1 (HIF-1). Mol. Pharmacol.
70: 1469-1480
[Abstract]
[Full Text]
-
Oda, T., Hirota, K., Nishi, K., Takabuchi, S., Oda, S., Yamada, H., Arai, T., Fukuda, K., Kita, T., Adachi, T., Semenza, G. L., Nohara, R.
(2006). Activation of hypoxia-inducible factor 1 during macrophage differentiation. Am. J. Physiol. Cell Physiol.
291: C104-C113
[Abstract]
[Full Text]
-
Lopez-Lazaro, M.
(2006). HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?. FASEB J.
20: 828-832
[Abstract]
[Full Text]
-
Rissanen, E., Tranberg, H. K., Sollid, J., Nilsson, G. E., Nikinmaa, M.
(2006). Temperature regulates hypoxia-inducible factor-1 (HIF-1) in a poikilothermic vertebrate, crucian carp (Carassius carassius). J. Exp. Biol.
209: 994-1003
[Abstract]
[Full Text]
-
Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., Katschinski, D. M.
(2005). Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors. Cancer Res.
65: 11094-11100
[Abstract]
[Full Text]
-
Choi, K.-O., Lee, T., Lee, N., Kim, J.-H., Yang, E. G., Yoon, J. M., Kim, J. H., Lee, T. G., Park, H.
(2005). Inhibition of the Catalytic Activity of Hypoxia-Inducible Factor-1{alpha}-Prolyl-Hydroxylase 2 by a MYND-Type Zinc Finger. Mol. Pharmacol.
68: 1803-1809
[Abstract]
[Full Text]
-
Biju, M. P., Akai, Y., Shrimanker, N., Haase, V. H.
(2005). Protection of HIF-1-deficient primary renal tubular epithelial cells from hypoxia-induced cell death is glucose dependent. Am. J. Physiol. Renal Physiol.
289: F1217-F1226
[Abstract]
[Full Text]
-
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., Ratcliffe, P. J.
(2005). Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma. Mol. Cell. Biol.
25: 5675-5686
[Abstract]